News

Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy
Personalis, Inc. (NASDAQ: PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can ...
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the ...
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase ...
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...